Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
Protocol ID
SJiMB21
Disease (Sub Disease)
Medulloblastoma
Diagnosis Stage
Newly diagnosed
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Links
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 2
Age Eligibility
up to 59 Months
International registry ID's
NCT05535166
| Study Title | Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma |
|---|---|
| Protocol ID | SJiMB21 |
| Disease (Sub Disease) | Medulloblastoma |
| Diagnosis Stage | Newly diagnosed |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ St. Jude Children's Research Hospital |
| Links | https://clinicaltrials.gov/ct2/show/NCT05535166 |
| Trial Status | Preparing to Open |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | up to 59 Months |
| International registry ID's | NCT05535166 |